Key finding
Resistance to dolutegravir among people living with HIV-1 infection is currently rare but not negligible, especially when it occurs concurrently with nucleotide reverse transcriptase inhibitors (NRTIs) resistance. This global study was conducted by Swiss, German, French, English, and South African researchers and appeared online in the journal Lancet ...